Crispr Therapeutics Stock: Bull vs. Bear
Crispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology. The biotech company is submitting its candidate to treat blood disorders to regulators in the U.S., Europe, and the U.K. this month. If regulators give Crispr the nod, it may soon reach the major milestone of product commercialization.